Drug · CHEMBL480

LANSOPRAZOLE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. LANSOPRAZOLE. Drugs and targets, record CHEMBL480. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL480

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: LANSOPRAZOLE; ChEMBL
ChEMBL ID: CHEMBL480; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Lansoprazole component of prevpac, Opiren, Prevacid, Prevacid 24 hr, Prevacid delayed release, Prevacid iv, Prevacid solutab, Zoton; ChEMBL
Other names: A-65006, AG-1749, Agopton, Lansoprazol, Lansox, Lanzoprazole, Lanzor, Limpidex, NSC-758638, Ogast, Ogastoro, Prevonco, Takepron; ChEMBL
DrugBank: DB00448; DrugBank
InChIKey: MJIHNNLFOKEZEW-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 12 of its 35 diseases, from ATC, DailyMed and PMDA; Open Targets

Targets2

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
ATP4A	Potassium-transporting ATPase	Potassium-transporting ATPase inhibitor	INHIBITOR	https://conductscience.org/library/genes/495
ATP4B	Potassium-transporting ATPase	Potassium-transporting ATPase inhibitor	INHIBITOR	https://conductscience.org/library/genes/496

Source ChEMBL

Diseases35

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
gastroesophageal reflux disease	Approval	ATC and DailyMed	40	23	https://conductscience.org/library/drugs?q=MONDO_0007186
Helicobacter pylori infectious disease	Phase 3	ClinicalTrials.gov	12	12	https://conductscience.org/library/drugs?q=MONDO_0006781
duodenal ulcer	Approval	DailyMed and PMDA	8	4	https://conductscience.org/library/drugs?q=MONDO_0005412
Laryngopharyngeal Reflux	Phase 1	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=EFO_1001355
type 1 diabetes mellitus	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005147
asthma	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0004979
diffuse large B-cell lymphoma	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0018905
peptic esophagitis	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0006896
triple-negative breast carcinoma	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005494
gastric ulcer	Approval	DailyMed and PMDA	14	1	https://conductscience.org/library/drugs?q=MONDO_0001126

1 to 10 of 35Source Open Targets

See all 35 diseases

Trials164

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT04124926	Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis	Phase 3	1,027	2022-07-29	lansoprazole	Its name	ClinicalTrials.gov
NCT02388737	Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis	Phase 3	703	2020-02-21	lansoprazole	Its name	ClinicalTrials.gov
NCT03050359	Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection	Phase 3	533	2020-06-12	lansoprazole	Its name	ClinicalTrials.gov
NCT01135368	Safety and Efficacy of Lansoprazole in Patients With Reflux Disease	Phase 4	506	2012-09-03	lansoprazole	Its name	ClinicalTrials.gov
NCT02388724	Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis	Phase 3	481	2019-06-03	lansoprazole	Its name	ClinicalTrials.gov
NCT00762359	A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers	Phase 3	461	2011-05-10	lansoprazole	Its name	ClinicalTrials.gov
NCT00787254	Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs	Phase 3	366	2011-05-10	lansoprazole	Its name	ClinicalTrials.gov
NCT00442013	Lansoprazole to Treat Children With Asthma	Phase 4	306	2012-12-06	lansoprazole	Its name	ClinicalTrials.gov
NCT05055128	A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole	Phase 2	248	2023-11-01	lansoprazole	Its name	ClinicalTrials.gov
NCT01008696	An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis	Phase 4	217	2013-08-13	lansoprazole	Its name	ClinicalTrials.gov

1 to 10 of 164

See all 164 trials

Comparisons in its trials55

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
TAK-438 20 mg vs Lansoprazole 30 mg: deaths from any cause	0 of 263	0 of 268	531	NCT03050359	Trial comparisons
TAK-438 20 mg vs Lansoprazole 30 mg: serious adverse events	1 of 263	3 of 268	531	NCT03050359	Trial comparisons
Vonoprazan 20 mg vs Lansoprazole 30 mg: Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)	93 of 244	86 of 235	479	NCT02388724	Trial comparisons
Vonoprazan 20 mg vs Lansoprazole 30 mg: deaths from any cause	0 of 244	0 of 235	479	NCT02388724	Trial comparisons
Vonoprazan 20 mg vs Lansoprazole 30 mg: serious adverse events	3 of 244	3 of 235	479	NCT02388724	Trial comparisons
Lansoprazole 15 mg QD vs Gefarnate 50 mg BID: Number of Participants With Gastric or Duodenal Ulcer or Gastric or Duodenal Hemorrhagic Lesion (Upper Gastrointestinal Hemorrhage)	7 of 226	56 of 234	460	NCT00762359	Trial comparisons
Lansoprazole 15 mg QD vs Gefarnate 50 mg BID: Number of Participants With Gastric Ulcer and/or Duodenal Ulcer	6 of 226	53 of 234	460	NCT00762359	Trial comparisons
Lansoprazole 15 mg QD vs Gefarnate 50 mg BID: serious adverse events	27 of 226	26 of 234	460	NCT00762359	Trial comparisons
Lansoprazole 15 mg QD vs Gefarnate 50 mg BID: Number of Participants With Gastric or Duodenal Ulcer or Gastric or Duodenal Hemorrhagic Lesion (Upper Gastrointestinal Hemorrhage)	15 of 183	52 of 181	364	NCT00787254	Trial comparisons
Lansoprazole 15 mg QD vs Gefarnate 50 mg BID: Number of Participants With Gastric Ulcer and/or Duodenal Ulcer	15 of 183	46 of 181	364	NCT00787254	Trial comparisons

1 to 10 of 55

See all 55 comparisons in its trials

Papers from its trials93

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31152740	RESULT	1	PubMed
30851041	RESULT	1	PubMed
30522654	RESULT	1	PubMed
28886622	RESULT	1	PubMed
26751904	RESULT	1	PubMed
25835348	RESULT	1	PubMed
25286881	RESULT	1	PubMed
24997559	RESULT	1	PubMed
23856153	RESULT	1	PubMed
22688850	RESULT	1	PubMed

1 to 10 of 93

See all 93 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL480

GET https://conductscience.org/api/drugs/v1/CHEMBL480/diseases?page=2

API reference For AI assistants